Director Katie Peng receives 4,200 Adicet Bio (ACET) stock options at $8.10

Rhea-AI Filing Summary

Adicet Bio director Katie Peng reported receiving a grant of stock options covering 4,200 shares of Adicet Bio common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. According to the grant terms, all 4,200 options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as she continues serving on the board. After this award, she holds 4,200 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peng Katie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 4,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 4,200 options Exercise price: $8.10 per share Expiration date: June 20, 2036 +2 more

5 metrics

Stock options granted 4,200 options Grant to director Katie Peng

Exercise price $8.10 per share Stock option strike price

Expiration date June 20, 2036 Option term end

Underlying shares 4,200 shares Common stock underlying options

Holdings after transaction 4,200 options Total derivative holdings reported

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "8.1000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-20T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:26 PM Accepted by SEC EDGAR 06/23/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peng Katie

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/21/2026		A		4,200		(1)	06/20/2036	Common Stock	4,200	$0	4,200	D

Explanation of Responses:

1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adicet Bio (ACET) director Katie Peng report in this Form 4?

Director Katie Peng reported receiving a grant of stock options for 4,200 shares of Adicet Bio common stock. These options are a compensation-related award rather than an open-market stock purchase or sale, and represent her reported derivative holdings after the transaction.

How many Adicet Bio (ACET) shares are covered by Katie Peng’s new stock options?

The grant covers stock options on 4,200 shares of Adicet Bio common stock. These options give her the right to buy that number of shares in the future, subject to vesting conditions and payment of the stated exercise price per share.

What is the exercise price and expiration date of Katie Peng’s Adicet Bio options?

The options have an exercise price of $8.10 per share and expire on June 20, 2036. This means she can choose to buy shares at $8.10 any time after vesting and before the June 2036 expiration date, subject to plan terms.

When do Katie Peng’s Adicet Bio (ACET) stock options vest?

All 4,200 options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Vesting is conditional on her continued service on Adicet Bio’s board of directors through that vesting date, per the award terms.

Does this Adicet Bio Form 4 show Katie Peng buying or selling stock on the market?

No, the Form 4 shows a grant of stock options as compensation, not an open-market trade. The transaction is coded as a grant or award acquisition, giving her rights to buy shares later, rather than reflecting an immediate purchase or sale of common stock.